Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin, bendamustine and rituximab in relapsed/refractory mantle cell lymphoma
2021-006030-40Phase 2Active
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I, Division of Oncology
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, bendamustine and rituximab in mantle cell lymphoma (MCL), sponsored by Medical University of Vienna, Department of Internal Medicine I, Division of Oncology. Primary endpoints: Best objective response rate, Progression-free survival and 2 more. Started Apr 2022; status: active.
02
Drugs
polatuzumab vedotinbendamustinerituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2021-006030-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006030-40.